Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 2/19/14  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Renier J. Brentjens

Wrong Dr. Renier J. Brentjens?

Director of Cellular Therapeutics

Memorial Sloan Kettering
Phone: (212) ***-****  HQ Phone
Memorial Sloan-Kettering Cancer Center
Memorial Sloan-Kettering Cancer Center Program1275 York Avenue
New York, New York 10065
United States

Company Description: Memorial Sloan-Kettering Cancer Center is the world's oldest and largest institution devoted to prevention, patient care, research and education in cancer. Our...   more
Background

Employment History

Board Memberships and Affiliations

  • Associate Member On the Faculty
    MSKCC

Education

  • MD
    SUNY Buffalo
  • PhD , microbiology
    SUNY Buffalo
54 Total References
Web References
"Memorial Sloan Kettering was ...
www.eurekalert.org, 19 Feb 2014 [cached]
"Memorial Sloan Kettering was the first center to report successful outcomes using this CD19-targeted approach in B-ALL patients," said Renier Brentjens, MD, PhD, Director of Cellular Therapeutics at Memorial Sloan Kettering and one of the study's senior authors.
...
Editor's note: Dr. Sadelain and Dr. Brentjens are co-holders of a patent that covers the technology used to create the modified T cells in this study.
"A game-changer," said Dr. Renier ...
www.ndtv.com, 15 Oct 2013 [cached]
"A game-changer," said Dr. Renier J. Brentjens, a leukemia specialist at Memorial Sloan-Kettering Cancer Center.
"There are people in [the] industry ...
www.weizmann-usa.org, 20 May 2013 [cached]
"There are people in [the] industry who feel this is the future . . . for cancer," said Renier J. Brentjens, a leukemia specialist working on CARs at Memorial Sloan-Kettering Cancer Center.
DR. RENIER ...
junotherapeutics.com, 4 Dec 2013 [cached]
DR. RENIER BRENTJENS
...
DR. RENIER BRENTJENS
Scientific co-founder
Dr Brentjens obtained an MD/PhD (microbiology) from SUNY Buffalo, completed residency in medicine at Yale-New Haven Hospital, and a medical oncology fellowship at Memorial Sloan-Kettering Cancer Center (MSKCC). Currently, Dr Brentjens is an associate member on the faculty at MSKCC and an attending physician on the Leukemia Service. As a medical oncology fellow at MSKCC, Dr Brentjens initiated the initial pre-clinical studies demonstrating the potential clinical application of autologous T cells genetically modified to target the CD19 antigen through the retroviral gene transfer of artificial T cell receptors termed chimeric antigen receptors (CARs). Following completion of his medical oncology training, Dr Brentjens became the principle investigator of his own laboratory. As a PI, Dr Brentjens successfully translated these studies to the clinical setting, treating patients with relapsed CD19+ tumors including chronic lymphocytic leukemia (CLL) and B cell acute lymphoblastic leukemia (B-ALL). Ongoing pre-clinical research in the laboratory is focused on the further development of CAR modified T cells designed to overcome the hostile immunosuppressive tumor microenvironment through the generation of "armored CAR T cells" currently being translated to the clinical setting as second generation CAR modified T cell clinical trials. Additionally, work in the Brentjens' lab has expanded this CAR technology to target additional tumor antigens.
More Info on Dr. Brentjens
"The immune system has evolved to ...
www.eurekalert.org, 18 Sept 2007 [cached]
"The immune system has evolved to police the body for infections and diseased cells, but it has a difficult time recognizing malignant cells since they largely appear normal to the immune system," said lead study author, Renier J. Brentjens, M.D., Ph.D., medical oncologist in the Leukemia Service at MSKCC."The idea is that we can take a patient's own T cells, re-educate them by inserting a gene into them that will enable them to produce a receptor to recognize B cell cancers, and then return them to the patient where they should be able to attack and kill the tumor cells."
Because the technique uses a patient's own T cells, there is little risk of compatibility issues or rejection, as there might be with human stem cell transplant, Dr. Brentjens adds.Human stem cell transplant, following radiation or chemotherapy, is currently incorporated into the treatment of several B cell malignancies.
In order to get T cells to recognize B cells, Dr. Brentjens and his colleagues created a gene that encodes for a cell-surface protein - an artificial T cell receptor called a chimeric antigen receptor -- designed to specifically bind to CD19, a molecule found on the surface of B cells and B cell cancers.Antigen receptors are what allow T cells, in combination with other parts of the immune system, to recognize and attack infected or malignant cells.This chimeric gene, formed from active portions of several immune system-related genes, creates the chimeric antigen receptor protein called 19-28z, which does not require other co-stimulatory signals to fully activate T cells, according to Dr. Brentjens.
Dr. Brentjens and his colleagues used an engineered retrovirus to insert the chimeric antigen receptor gene into T cell DNA.
...
"The repeated boosts of new T cells during therapy to improve T cell persistence enhances the efficacy of these T cells in eradicating cancerous B cells," said Dr. Brentjens."This concept of T cell persistence being critical to treatment efficacy is one we are further investigating in current and upcoming clinical trials."
The results have given the researchers further evidence that the technique will work in humans.When transplanted back into a patient, these engineered T cells could then attack and kill tumor cells bearing the CD19 protein."CD19 is not found on the surface of bone marrow stem cells, so these modified T cells are reasonably safe since they should not attack other blood forming cells in the bone marrow following treatment," Dr. Brentjens said.
Based on the results of their findings, the MSKCC researchers are currently conducting a clinical trial using this method in patients with chemotherapy-resistant CLL.CLL is currently considered an incurable cancer, Dr.
Brentjens said, although the disease generally progresses slowly.
Other People with the name "Brentjens":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.